Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Robert Orlowski
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Disorders
Physiology
Procedures
Concepts & Ideas
Anatomy
Phenomena
Sign-in to see full Profile
Network (preview)
10
Voorhees, Peter
9
Small, George
7
Dees, Claire
7
Esseltine, Dixie
6
Jagannath, Sundar
6
Shi, Yue
6
Kuhn, Deborah J.
5
Anderson, Kenneth
4
Bladé, Joan
4
Barlogie, Bart
4
Moore, Dominic
4
Somasundaram, Sivagurunathan
3
Zhuang, Sen
3
Mitchell, Beverly
3
Shea, Thomas
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Robert Orlowski (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Shah J J; Orlowski R Z
Proteasome inhibitors in the treatment of multiple myeloma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(11):1964-79.
-
2009: Voorhees Peter M; Chen Qing; Small George W; Kuhn Deborah J; Hunsucker Sally A; Nemeth Jeffrey A; Orlowski Robert Z
Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.
British journal of haematology 2009;145(4):481-90.
-
2009: Kuhn Deborah J; Hunsucker Sally A; Chen Qing; Voorhees Peter M; Orlowski Marian; Orlowski Robert Z
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.
Blood 2009;113(19):4667-76.
-
2008: Bladé Joan; Sonneveld Pieter; San Miguel Jesús F; Sutherland Heather J; Hajek Roman; Nagler Arnon; Spencer Andrew; Robak Tadeusz; Cibeira M Teresa; Zhuang Sen H; Harousseau Jean-Luc; Orlowski Robert Z;
Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.
Clinical lymphoma & myeloma 2008;8(6):352-5.
-
2008: Dees E Claire; O'Neil Bert H; Lindley Celeste M; Collichio Frances; Carey Lisa A; Collins Jason; Riordan William J; Ivanova Anastasia; Esseltine Dixie; Orlowski Robert Z
A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
Cancer chemotherapy and pharmacology 2008;63(1):99-107.
-
2008: Jones Richard J; Chen Qing; Voorhees Peter M; Young Ken H; Bruey-Sedano Nathalie; Yang Dajun; Orlowski Robert Z
Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(17):5416-25.
-
2008: Chen Qing; Xie Weilin; Kuhn Deborah J; Voorhees Peter M; Lopez-Girona Antonia; Mendy Derek; Corral Laura G; Krenitsky Veronique Plantevin; Xu Weiming; Moutouh-de Parseval Laure; Webb David R; Mercurio Frank; Nakayama Keiichi I; Nakayama Keiko; Orlowski Robert Z
Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.
Blood 2008;111(9):4690-9.
-
2008: Sonneveld Pieter; Hajek Roman; Nagler Arnon; Spencer Andrew; Bladé Joan; Robak Tadeusz; Zhuang Sen H; Harousseau Jean-Luc; Orlowski Robert Z;
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Cancer 2008;112(7):1529-37.
-
2008: Orlowski Robert Z; Kuhn Deborah J
Proteasome inhibitors in cancer therapy: lessons from the first decade.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(6):1649-57.
-
2007: Voorhees Peter M; Chen Qing; Kuhn Deborah J; Small George W; Hunsucker Sally A; Strader John S; Corringham Robert E; Zaki Mohamed H; Nemeth Jeffrey A; Orlowski Robert Z
Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(21):6469-78.
-
2007: Kuhn Deborah J; Chen Qing; Voorhees Peter M; Strader John S; Shenk Kevin D; Sun Congcong M; Demo Susan D; Bennett Mark K; van Leeuwen Fijs W B; Chanan-Khan Asher A; Orlowski Robert Z
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Blood 2007;110(9):3281-90.
-
2007: Stadtmauer Edward A; Lonial Sagar; Vesole David H; Abonour Rafat; Alsina Melissa; Badros Ashraf; Comenzo Raymond; Durie Brian; Giralt Sergio; Hussein Mohamad; Jakubowiak Andrzej; Mehta Jayesh; Niesvizky Ruben; Orlowski Robert; Siegel David; Singhal Seema; Vescio Robert; Wang Michael; Zangari Maurizio; Munshi Nikhil C
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
Clinical advances in hematology & oncology : H&O 2007;5(10 Suppl 15):7-19, quiz 21-2.
-
2007: Orlowski Robert Z; Nagler Arnon; Sonneveld Pieter; Bladé Joan; Hajek Roman; Spencer Andrew; San Miguel Jesús; Robak Tadeusz; Dmoszynska Anna; Horvath Noemi; Spicka Ivan; Sutherland Heather J; Suvorov Alexander N; Zhuang Sen H; Parekh Trilok; Xiu Liang; Yuan Zhilong; Rackoff Wayne; Harousseau Jean-Luc
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(25):3892-901.
-
2007: Kyle Robert A; Yee Gary C; Somerfield Mark R; Flynn Patrick J; Halabi Susan; Jagannath Sundar; Orlowski Robert Z; Roodman David G; Twilde Patricia; Anderson Kenneth;
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(17):2464-72.
-
2007: Small George W; Shi Yue Y; Higgins Linda S; Orlowski Robert Z
Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance.
Cancer research 2007;67(9):4459-66.
-
2007: Voorhees Peter M; Orlowski Robert Z
Emerging data on the use of anthracyclines in combination with bortezomib in multiple myeloma.
Clinical lymphoma & myeloma 2007;7 Suppl 4():S156-62.
-
2007: Biehn Suzanne E; Moore Dominic T; Voorhees Peter M; Garcia Reynaldo A; Lehman Mary Jo; Dees E Claire; Orlowski Robert Z
Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin.
Annals of hematology 2007;86(3):211-6.
-
2006: Ryan David P; O'Neil Bert H; Supko Jeffrey G; Rocha Lima Carlo M; Dees E Claire; Appleman Leonard J; Clark Jeffrey; Fidias Phinos; Orlowski Robert Z; Kashala Oscar; Eder Joseph P; Cusack James C
A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.
Cancer 2006;107(11):2688-97.
-
2006: Biehn Suzanne E; Kirk David; Rivera M Patricia; Martinez Antonio E; Khandani Amir H; Orlowski Robert Z
Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.
Hematological oncology 2006;24(4):234-7.
-
2006: Shi Yue Y; Small George W; Orlowski Robert Z
Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
Breast cancer research and treatment 2006;100(1):33-47.
-
2006: Voorhees Peter M; Orlowski Robert Z
Emerging role of novel combinations for induction therapy in multiple myeloma.
Clinical lymphoma & myeloma 2006;7(1):33-41.
-
2006: Richardson Paul G; Briemberg Hannah; Jagannath Sundar; Wen Patrick Y; Barlogie Bart; Berenson James; Singhal Seema; Siegel David S; Irwin David; Schuster Michael; Srkalovic Gordan; Alexanian Raymond; Rajkumar S Vincent; Limentani Steven; Alsina Melissa; Orlowski Robert Z; Najarian Kevin; Esseltine Dixie; Anderson Kenneth C; Amato Anthony A
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):3113-20.
-
2006: Dees E Claire; Orlowski Robert Z
Targeting the ubiquitin-proteasome pathway in breast cancer therapy.
Future oncology (London, England) 2006;2(1):121-35.
-
2006: Orlowski Robert Z; Zeger Erik L
Targeting the proteasome as a therapeutic strategy against haematological malignancies.
Expert opinion on investigational drugs 2006;15(2):117-30.
-
2006: Orlowski Robert Z
Is bortezomib superior to high-dose dexamethasone for the treatment of relapsed multiple myeloma?
Nature clinical practice. Oncology 2006;3(1):16-7.
-
2006: San Miguel Jesús; Bladé Joan; Boccadoro Mario; Cavenagh Jamie; Glasmacher Axel; Jagannath Sundar; Lonial Sagar; Orlowski Robert Z; Sonneveld Pieter; Ludwig Heinz
A practical update on the use of bortezomib in the management of multiple myeloma.
The oncologist 2006;11(1):51-61.
-
2006: Orlowski Robert Z
Initial therapy of multiple myeloma patients who are not candidates for stem cell transplantation.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2006;():338-47.
-
2006: Voorhees Peter M; Orlowski Robert Z
The proteasome and proteasome inhibitors in cancer therapy.
Annual review of pharmacology and toxicology 2006;46():189-213.
-
2005: Lonial Sagar; Waller Edmund K; Richardson Paul G; Jagannath Sundar; Orlowski Robert Z; Giver Cynthia R; Jaye David L; Francis Dixil; Giusti Sara; Torre Claire; Barlogie Bart; Berenson James R; Singhal Seema; Schenkein David P; Esseltine Dixie-Lee W; Anderson Jessica; Xiao Hugh; Heffner Leonard T; Anderson Kenneth C;
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
Blood 2005;106(12):3777-84.
-
2005: Ramaswamy Bhuvaneswari; Povoski Steven P; Rhoades Chris; Allen Joan; Hauger Marsha; Young Donn; Burak William; Farrar William; Yee Lisa; Kendra Kari; Somasundaram Sivagurunathan; Orlowski Robert Z; Shapiro Charles L
Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer.
Breast cancer research and treatment 2005;93(1):67-74.
-
2005: Orlowski Robert Z; Voorhees Peter M; Garcia Reynaldo A; Hall Melissa D; Kudrik Fred J; Allred Tammy; Johri Anandhi R; Jones Paul E; Ivanova Anastasia; Van Deventer Hendrik W; Gabriel Don A; Shea Thomas C; Mitchell Beverly S; Adams Julian; Esseltine Dixie-Lee; Trehu Elizabeth G; Green Marie; Lehman Mary Jo; Natoli Susan; Collins Jason M; Lindley Celeste M; Dees E Claire
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
Blood 2005;105(8):3058-65.
-
2005: Jagannath Sundar; Barlogie Bart; Berenson James R; Singhal Seema; Alexanian Raymond; Srkalovic Gordan; Orlowski Robert Z; Richardson Paul G; Anderson Jessica; Nix Darrell; Esseltine Dixie L; Anderson Kenneth C;
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Cancer 2005;103(6):1195-200.
-
2005: Orlowski Robert Z;
Bortezomib therapy following first relapse.
Oncology (Williston Park, N.Y.) 2005;19(1):23-6.
-
2005: Orlowski Robert Z
The ubiquitin proteasome pathway from bench to bedside.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2005;():220-5.
-
2005: Orlowski Robert Z
Proteasome inhibitors in cancer therapy.
Methods in molecular biology (Clifton, N.J.) 2005;301():339-50.
-
2004: Small George W; Shi Yue Y; Edmund Natalie A; Somasundaram Sivagurunathan; Moore Dominic T; Orlowski Robert Z
Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role.
Molecular pharmacology 2004;66(6):1478-90.
-
2004: Orlowski Robert Z
Bortezomib in combination with other therapies for the treatment of multiple myeloma.
Journal of the National Comprehensive Cancer Network : JNCCN 2004;2 Suppl 4():S16-20.
-
2004: Orlowski Robert Z; Mills Sharon R; Hartley Eric E; Ye Xiaobu; Piantadosi Steven; Ambinder Richard F; Gore Steven D; Miller Carole B
Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia.
Leukemia & lymphoma 2004;45(11):2215-9.
-
2004: Orlowski Robert Z
Bortezomib and its role in the management of patients with multiple myeloma.
Expert review of anticancer therapy 2004;4(2):171-9.
-
2004: Orlowski Robert Z
Successful pregnancy after cladribine therapy for hairy cell leukemia.
Leukemia & lymphoma 2004;45(1):187-8.
-
2003: Voorhees Peter M; Dees E Claire; O'Neil Bert; Orlowski Robert Z
The proteasome as a target for cancer therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(17):6316-25.
-
2003: Small George W; Somasundaram Sivagurunathan; Moore Dominic T; Shi Yue Y; Orlowski Robert Z
Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK.
The Journal of pharmacology and experimental therapeutics 2003;307(3):861-9.
-
2003: Richardson Paul G; Barlogie Bart; Berenson James; Singhal Seema; Jagannath Sundar; Irwin David; Rajkumar S Vincent; Srkalovic Gordan; Alsina Melissa; Alexanian Raymond; Siegel David; Orlowski Robert Z; Kuter David; Limentani Steven A; Lee Stephanie; Hideshima Teru; Esseltine Dixie-Lee; Kauffman Michael; Adams Julian; Schenkein David P; Anderson Kenneth C
A phase 2 study of bortezomib in relapsed, refractory myeloma.
The New England journal of medicine 2003;348(26):2609-17.
-
2003: Orlowski Robert Z; Dees E Claire
The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer.
Breast cancer research : BCR 2003;5(1):1-7.
-
2002: Orlowski Robert Z; Stinchcombe Thomas E; Mitchell Beverly S; Shea Thomas C; Baldwin Albert S; Stahl Stephanie; Adams Julian; Esseltine Dixie-Lee; Elliott Peter J; Pien Christine S; Guerciolini Roberto; Anderson Jessica K; Depcik-Smith Natalie D; Bhagat Rita; Lehman Mary Jo; Novick Steven C; O'Connor Owen A; Soignet Steven L
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(22):4420-7.
-
2002: van Deventer Hendrik W; Hall Melissa D; Orlowski Robert Z; Mitchell Beverly S; Berkowitz Lee R; Hogan Cathe; Dunphy Cherie H; Koehler Julie; Shea Thomas C
Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia.
American journal of hematology 2002;71(3):184-90.
-
2002: Orlowski Robert Z; Baldwin Albert S
NF-kappaB as a therapeutic target in cancer.
Trends in molecular medicine 2002;8(8):385-9.
-
2002: Orlowski Robert Z; Small George W; Shi Yue Y
Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis.
The Journal of biological chemistry 2002;277(31):27864-71.
-
2002: Somasundaram Sivagurunathan; Edmund Natalie A; Moore Dominic T; Small George W; Shi Yue Y; Orlowski Robert Z
Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer.
Cancer research 2002;62(13):3868-75.
-
2002: Small George W; Chou Teh-Ying; Dang Chi V; Orlowski Robert Z
Evidence for involvement of calpain in c-Myc proteolysis in vivo.
Archives of biochemistry and biophysics 2002;400(2):151-61.
-
1999: Orlowski R Z
The role of the ubiquitin-proteasome pathway in apoptosis.
Cell death and differentiation 1999;6(4):303-13.
Sign-in to see more
